MedTrace Logo

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

NCT06589830 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-28

No results posted yet for this study

Summary

This is a Phase II trial designed to determine the optimal dose and evaluate the effectiveness of TL938 and trastuzumab in treating patients with HER2+ colorectal cancer that has metastasized or recurred and is inoperable.

Conditions

  • Colorectal Cancer Metastatic
  • Advanced Colorectal Cancer

Interventions

DRUG

TL938 Capsules

Oral administration

DRUG

Trastuzumab

Intravenous (IV) infusion

Sponsors & Collaborators

  • Suzhou Teligene Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-13
Primary Completion
2026-10-31
Completion
2027-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06589830 on ClinicalTrials.gov